ConvaTec Group - CTEC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 301.67
  • Forecasted Upside: 37.00%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
GBX 220.20
▼ -0.8 (-0.36%)

This chart shows the closing price for CTEC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ConvaTec Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CTEC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CTEC

Analyst Price Target is GBX 301.67
▲ +37.00% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for ConvaTec Group in the last 3 months. The average price target is GBX 301.67, with a high forecast of GBX 310 and a low forecast of GBX 290. The average price target represents a 37.00% upside from the last price of GBX 220.20.

This chart shows the closing price for CTEC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in ConvaTec Group. This rating has held steady since August 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/2/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/30/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/6/2024Berenberg BankReiterated RatingBuyGBX 310
7/31/2024Royal Bank of CanadaLower TargetOutperformGBX 320 ➝ GBX 305
7/31/2024JPMorgan Chase & Co.Lower TargetOverweightGBX 323 ➝ GBX 290
6/11/2024Berenberg BankReiterated RatingBuyGBX 310
3/7/2024JPMorgan Chase & Co.Boost TargetOverweightGBX 300 ➝ GBX 323
3/6/2024Berenberg BankBoost TargetBuyGBX 290 ➝ GBX 310
11/15/2023Berenberg BankReiterated RatingBuyGBX 290
11/15/2023Jefferies Financial GroupReiterated RatingBuyGBX 300
9/7/2023Royal Bank of CanadaUpgradeOutperformGBX 215 ➝ GBX 300
9/6/2023BarclaysReiterated RatingOverweightGBX 310
9/5/2023The Goldman Sachs GroupInitiated CoverageBuyGBX 300
6/27/2023JPMorgan Chase & Co.Reiterated RatingOverweightGBX 290
6/8/2023JPMorgan Chase & Co.Lower TargetOverweightGBX 305 ➝ GBX 290
5/19/2023BarclaysBoost TargetOverweightGBX 295 ➝ GBX 300
3/23/2023Royal Bank of CanadaReiterated RatingSector PerformGBX 215
3/7/2023JPMorgan Chase & Co.Reiterated RatingOverweight
11/18/2022JPMorgan Chase & Co.Boost TargetOverweightGBX 275 ➝ GBX 281
11/17/2022Berenberg BankReiterated RatingBuyGBX 280
11/11/2022BarclaysBoost TargetOverweightGBX 290 ➝ GBX 295
10/10/2022BarclaysLower TargetOverweightGBX 295 ➝ GBX 290
9/8/2022Berenberg BankBoost TargetBuyGBX 250 ➝ GBX 280
8/11/2022Royal Bank of CanadaReiterated RatingSector PerformGBX 210
8/5/2022JPMorgan Chase & Co.Boost TargetOverweightGBX 255 ➝ GBX 275
8/5/2022BarclaysBoost TargetOverweightGBX 285 ➝ GBX 295
7/4/2022BarclaysReiterated RatingOverweightGBX 285
6/27/2022JPMorgan Chase & Co.Boost TargetOverweightGBX 230 ➝ GBX 255
5/31/2022BarclaysLower TargetOverweightGBX 290 ➝ GBX 285
5/18/2022JPMorgan Chase & Co.Reiterated RatingOverweightGBX 230
5/18/2022Berenberg BankReiterated RatingBuyGBX 250
5/18/2022Royal Bank of CanadaUpgradeSector PerformGBX 195 ➝ GBX 210
4/13/2022Berenberg BankReiterated RatingBuyGBX 250
3/24/2022Royal Bank of CanadaReiterated RatingUnderperformGBX 195
3/23/2022Berenberg BankReiterated RatingBuyGBX 250
3/16/2022Berenberg BankInitiated CoverageBuyGBX 250
3/8/2022BarclaysLower TargetOverweightGBX 295 ➝ GBX 290
2/4/2022Royal Bank of CanadaReiterated RatingUnderperformGBX 195
1/4/2022JPMorgan Chase & Co.Reiterated RatingOverweight
11/24/2021Royal Bank of CanadaLower TargetUnderperformGBX 213 ➝ GBX 195
11/1/2021CitigroupReiterated RatingNeutralGBX 235
11/1/2021JPMorgan Chase & Co.Boost TargetOverweightGBX 272 ➝ GBX 278
11/1/2021BarclaysBoost TargetOverweightGBX 275 ➝ GBX 290
10/29/2021Shore CapitalReiterated RatingBuy
9/9/2021JPMorgan Chase & Co.UpgradeOverweightGBX 229 ➝ GBX 272
8/10/2021Shore CapitalReiterated RatingBuy
8/9/2021Royal Bank of CanadaDowngradeUnderperformGBX 230 ➝ GBX 213
8/2/2021Credit Suisse GroupBoost TargetUnderperformGBX 200 ➝ GBX 215
8/2/2021JPMorgan Chase & Co.Boost TargetNeutralGBX 212 ➝ GBX 229
7/30/2021Shore CapitalReiterated RatingBuy
6/23/2021Numis SecuritiesReiterated RatingBuyGBX 310
6/1/2021Royal Bank of CanadaBoost TargetSector PerformGBX 200 ➝ GBX 230
5/11/2021Shore CapitalReiterated RatingBuy
4/29/2021Shore CapitalReiterated RatingBuy
3/11/2021Shore CapitalReiterated RatingBuy
11/2/2020Shore CapitalReiterated RatingHold
10/29/2020Credit Suisse GroupBoost TargetUnderperformGBX 185 ➝ GBX 190
10/29/2020JPMorgan Chase & Co.Boost TargetUnderweightGBX 175 ➝ GBX 176
9/29/2020Royal Bank of CanadaDowngradeSector PerformGBX 245 ➝ GBX 200
7/22/2020BarclaysReiterated RatingEqual weight
7/8/2020BarclaysReiterated RatingEqual weight
7/2/2020Morgan StanleyBoost TargetEqual weightGBX 206 ➝ GBX 208
7/2/2020Peel HuntReiterated RatingAdd
6/30/2020JPMorgan Chase & Co.Boost TargetUnderweightGBX 167 ➝ GBX 172
6/26/2020Peel HuntDowngradeAddGBX 220 ➝ GBX 225
6/18/2020CitigroupReiterated RatingNeutral
6/10/2020Royal Bank of CanadaUpgradeOutperformGBX 178 ➝ GBX 245
6/3/2020Peel HuntReiterated RatingBuy
5/20/2020Jefferies Financial GroupLower TargetBuyGBX 250 ➝ GBX 240
5/18/2020BarclaysBoost TargetEqual WeightGBX 182 ➝ GBX 190
5/1/2020CSFBBoost TargetUnderperformGBX 175 ➝ GBX 180
5/1/2020JPMorgan Chase & Co.Boost TargetUnderweightGBX 160 ➝ GBX 167
5/1/2020Credit Suisse GroupBoost TargetUnderperformGBX 175 ➝ GBX 180
5/1/2020UBS GroupBoost TargetBuyGBX 235 ➝ GBX 245
4/30/2020Shore CapitalReiterated RatingHold
4/30/2020Peel HuntReiterated RatingBuy
4/24/2020Peel HuntReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
4/1/2020JPMorgan Chase & Co.Lower TargetUnderweightGBX 177 ➝ GBX 160
3/30/2020Peel HuntReiterated RatingBuy
3/20/2020Royal Bank of CanadaLower TargetSector PerformerGBX 197 ➝ GBX 178
3/19/2020Peel HuntReiterated RatingBuy
3/12/2020Peel HuntLower TargetBuyGBX 250 ➝ GBX 220
3/5/2020Peel HuntReiterated RatingBuy
3/2/2020UBS GroupReiterated RatingBuy
3/2/2020JPMorgan Chase & Co.Boost TargetUnderweightGBX 168 ➝ GBX 177
2/24/2020Peel HuntReiterated RatingBuy
2/21/2020UBS GroupReiterated RatingBuy
2/18/2020BarclaysLower TargetEqual weightGBX 185 ➝ GBX 182
2/13/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
2/4/2020JPMorgan Chase & Co.Reiterated RatingUnderweightGBX 168
2/3/2020BarclaysReiterated RatingEqual weight
1/27/2020Peel HuntReiterated RatingBuy
1/23/2020Shore CapitalDowngradeHold
1/21/2020Jefferies Financial GroupBoost TargetBuyGBX 220 ➝ GBX 250
1/20/2020JPMorgan Chase & Co.DowngradeUnderweightGBX 171 ➝ GBX 168
1/10/2020UBS GroupUpgradeBuyGBX 185 ➝ GBX 235
1/7/2020Peel HuntReiterated RatingBuy
1/7/2020BarclaysReiterated RatingEqual weight
(Data available from 12/23/2019 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/27/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/25/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/24/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/23/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ConvaTec Group logo
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer. In addition, the company offers continence care products and services for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other causes, as well as critical care devices and products used in intensive care units and hospital settings. Further, it provides infusion care solutions comprising disposable infusion sets for diabetes insulin pumps, or for pumps used in continuous subcutaneous infusion treatments for conditions such as parkinson's disease. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. ConvaTec Group PLC was founded in 1978 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 220.20
Low: 218.61
High: 221.60

50 Day Range

MA: GBX 229.42
Low: 213.40
High: 264.40

52 Week Range

Now: GBX 220.20
Low: 211.80
High: 295.20

Volume

225,984,984 shs

Average Volume

7,696,888 shs

Market Capitalization

£4.51 billion

P/E Ratio

3,670.00

Dividend Yield

2.23%

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of ConvaTec Group?

The following equities research analysts have issued reports on ConvaTec Group in the last year: Berenberg Bank, JPMorgan Chase & Co., and Royal Bank of Canada.
View the latest analyst ratings for CTEC.

What is the current price target for ConvaTec Group?

0 Wall Street analysts have set twelve-month price targets for ConvaTec Group in the last year. Their average twelve-month price target is GBX 301.67, suggesting a possible upside of 37.0%. Berenberg Bank has the highest price target set, predicting CTEC will reach GBX 310 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of GBX 290 for ConvaTec Group in the next year.
View the latest price targets for CTEC.

What is the current consensus analyst rating for ConvaTec Group?

ConvaTec Group currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CTEC will outperform the market and that investors should add to their positions of ConvaTec Group.
View the latest ratings for CTEC.

What other companies compete with ConvaTec Group?

How do I contact ConvaTec Group's investor relations team?

ConvaTec Group's physical mailing address is 3 Forbury Place Floor 7, 23 Forbury Road, ICKENHAM, RG1 3JH, United Kingdom. The company's listed phone number is 44 11 8952 8100. The official website for ConvaTec Group is www.convatecgroup.com. Learn More about contacing ConvaTec Group investor relations.